ArticleCardiovascular diabetology2025
Myocardial interstitial fibrosis and subclinical left ventricular systolic dysfunction in type 2 diabetes mellitus patients with obesity: a 3.0 T MRI study.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Resistin in Tissue Remodeling and Fibrosis: A New Frontier.Biomolecules · 2026Review
- Research progress on the molecular mechanisms of tanshinone IIA in the treatment of cardiovascular and cerebrovascular diseases (Review).International journal of molecular medicine · 2026Review
- Pathogenesis of diabetic cardiomyopathy and emerging therapeutic strategies: a network-based perspective.Frontiers in clinical diabetes and healthcare · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundPatients with type 2 diabetes mellitus (T2DM) who are obese have increased risk of cardiovascular events. This study aimed to investigate the impact of obesity on myocardial interstitial fibrosis and its association with subclinical left ventricular (LV) systolic dysfunction in patients with T2DM.
methodsEighty-one T2DM patients without obesity, 48 patients with obesity and 40 matched lean healthy controls were prospectively recruited and underwent cardiac magnetic resonance imaging. Extracellular volume (ECV), 3-D feature tracking strain including LV radial (GRS), circumferential (GCS) and longitudinal (GLS) peak strains were evaluated from T1 mapping and cine images, and compared among the groups.
resultsCompared with controls, the LV GRS and GLS were significantly lower and ECV significantly higher in T2DM patients without obesity, and they were even lower or higher in patients with obesity than in both controls and patients without obesity. The LV GCS was significantly lower in patients with obesity than that in controls. Multivariable linear regression analyses demonstrated that obesity was independently associated with ECV (β = 2.147, p = 0.006), LV GRS and GLS (β = - 3.427 and 1.408, p = 0.019 and = 0.001, respectively) in patients with T2DM. When ECV was included in the regression analyses, both obesity and ECV were independently associated with LV GLS (β = 1.540 and 0.118, p < 0.001 and = 0.019, respectively).
conclusionsIn patients with T2DM, there was more severe myocardial interstitial fibrosis and subclinical LV systolic dysfunction in patients with obesity, and increased myocardial fibrosis is independently associated with impaired LV systolic function. These results indicate the potential clinical significance of weight management in T2DM patients with obesity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.